---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-005018"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:47:19.090341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aquestive to present Anaphylm data at AAAAI: symptom resolution in 12 min, stable under extreme conditions

## Summary
- Median symptom resolution time 12 min vs 74 min without treatment; mean angioedema resolution within 5 min.
- Anaphylm matched or exceeded IM epinephrine in all key PK parameters in Phase 2 OASIS study.
- Stability and potency maintained under extreme heat, freezing, and water submersion.
- Presentations at AAAAI Annual Meeting Feb 28 – Mar 3, 2025 in San Diego.

## SEC filing metadata
- accession: 0001628280-25-005018
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828025005018/0001628280-25-005018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828025005018/aqst-20250212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-005018
- JSON: https://secwatch.observer/filing/0001628280-25-005018.json
- Plain text: https://secwatch.observer/filing/0001628280-25-005018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.